-
公开(公告)号：US08058232B2
公开(公告)日：2011-11-15
申请号：US12614805
申请日：2009-11-09
申请人： Silvano Fumero , Luisa Bertarione Rava Rossa , Domenico G. Barone , Lila Drittanti , Thierry Guyon , Gilles Borrelly , Barbara Canepa , Chiara Lorenzetto
发明人： Silvano Fumero , Luisa Bertarione Rava Rossa , Domenico G. Barone , Lila Drittanti , Thierry Guyon , Gilles Borrelly , Barbara Canepa , Chiara Lorenzetto
CPC分类号： C07K14/47
摘要： The present invention relates to polypeptide variants of the HMGB-1 high affinity binding domain Box-A (HMGB1 Box-A) or to a biologically active fragment of HMGB1 Box-A, which are obtained through systematic mutations of single amino acids of the wild-type HMGB1 Box-A protein and which show an increased resistance to proteases and which are therefore characterized by more favorable pharmacokinetic and pharmacodynamic profiles. Moreover, the present invention concerns the use of said polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and associated with RAGE.
摘要翻译： 本发明涉及HMGB-1高亲和力结合域Box-A（HMGB1 Box-A）或HMGB1 Box-A的生物活性片段的多肽变体，其通过野生型单个氨基酸的系统性突变获得 型HMGB1 Box-A蛋白，其表现出对蛋白酶的增加的抗性，因此其特征在于更有利的药代动力学和药效学特征。 此外，本发明涉及HMGB1 Box-A的所述多肽分子用于诊断，预防，缓解和/或治疗与细胞外HMGB1相关并与RAGE相关的病理学的用途。
-
2.发明申请USE OF POLYPEPTIDES OBTAINED THROUGH SYSTEMATIC MUTATIONS OF SINGLE AMINO ACIDS OF HUMAN AND NON-HUMAN BOX-A OF HMGB1 TO PREVENT AND/OR ANTAGONIZE PATHOLOGIES INDUCED BY HMGB1 有权通过HMGB1人类和非人类BOX-A的单氨基酸的系统化突变获得的多肽的使用，以预防和/或拮抗HMGB1诱导的病理学公开(公告)号：US20110052493A1
公开(公告)日：2011-03-03
申请号：US12614805
申请日：2009-11-09
申请人： Silvano FUMERO , Luisa Bertarione Rava Rossa , Domenico G. Barone , Lila Drittanti , Thierry Guyon , Gilles Borrelly , Barbara Canepa , Chiara Lorenzetto
发明人： Silvano FUMERO , Luisa Bertarione Rava Rossa , Domenico G. Barone , Lila Drittanti , Thierry Guyon , Gilles Borrelly , Barbara Canepa , Chiara Lorenzetto
IPC分类号： A61K49/00 , C07K14/00 , C07H21/04 , C12N15/63 , C12P21/02 , A61K38/16 , A61K9/00 , A61K39/395 , A61P35/00 , A61P37/00 , A61P25/00
CPC分类号： C07K14/47
摘要： The present invention relates to polypeptide variants of the HMGB-1 high affinity binding domain Box-A (HMGB1 Box-A) or to a biologically active fragment of HMGB1 Box-A, which are obtained through systematic mutations of single amino acids of the wild-type HMGB1 Box-A protein and which show an increased resistance to proteases and which are therefore characterized by more favourable pharmacokinetic and pharmacodynamic profiles. Moreover, the present invention concerns the use of said polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and associated with RAGE.
摘要翻译： 本发明涉及HMGB-1高亲和力结合域Box-A（HMGB1 Box-A）或HMGB1 Box-A的生物活性片段的多肽变体，其通过野生型单个氨基酸的系统性突变获得 型HMGB1 Box-A蛋白，其表现出对蛋白酶的增加的抗性，因此其特征在于更有利的药代动力学和药效学特征。 此外，本发明涉及HMGB1 Box-A的所述多肽分子用于诊断，预防，缓解和/或治疗与细胞外HMGB1相关并与RAGE相关的病理学的用途。
-
3.发明授权Protease resistant mutant of human HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) 有权人HMGB1高亲和力结合域Box-A（HMGB1 Box-A）的蛋白酶抗性突变体公开(公告)号：US07635679B2
公开(公告)日：2009-12-22
申请号：US11713789
申请日：2007-03-05
申请人： Silvano Fumero , Luisa Bertarione Rava Rossa , Domenico G. Barone , Lila Drittanti , Thierry Guyon , Gilles Borrelly , Barbara Canepa , Chiara Lorenzetto
发明人： Silvano Fumero , Luisa Bertarione Rava Rossa , Domenico G. Barone , Lila Drittanti , Thierry Guyon , Gilles Borrelly , Barbara Canepa , Chiara Lorenzetto
CPC分类号： C07K14/47
摘要： The present invention relates to polypeptide variants of the HMGB-1 high affinity binding domain Box-A (HMGB1 Box-A) or to a biologically active fragment of HMGB1 Box-A, which are obtained through systematic mutations of single amino acids of the wild-type HMGB1 Box-A protein and which show an increased resistance to proteases and which are therefore characterized by more favorable pharmacokinetic and pharmacodynamic profiles. Moreover, the present invention concerns the use of said polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and associated with RAGE.
摘要翻译： 本发明涉及HMGB-1高亲和力结合域Box-A（HMGB1 Box-A）或HMGB1 Box-A的生物活性片段的多肽变体，其通过野生型单个氨基酸的系统性突变获得 型HMGB1 Box-A蛋白，其表现出对蛋白酶的增加的抗性，因此其特征在于更有利的药代动力学和药效学特征。 此外，本发明涉及HMGB1 Box-A的所述多肽分子用于诊断，预防，缓解和/或治疗与细胞外HMGB1相关并与RAGE相关的病理学的用途。
-
4.发明申请Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human Box-A of HMGB1 to prevent and/or antagonize pathologies induced by HMGB1 有权通过HMGB1的人和非人Box-A的单个氨基酸的系统性突变获得的多肽的使用来预防和/或拮抗由HMGB1诱导的病理学公开(公告)号：US20080038309A1
公开(公告)日：2008-02-14
申请号：US11713789
申请日：2007-03-05
申请人： Silvano Fumero , Luisa Bertarione Rava Rossa , Domenico Barone , Lila Drittanti , Thierry Guyon , Gilles Borrelly , Barbara Canepa , Chiara Lorenzetto
发明人： Silvano Fumero , Luisa Bertarione Rava Rossa , Domenico Barone , Lila Drittanti , Thierry Guyon , Gilles Borrelly , Barbara Canepa , Chiara Lorenzetto
IPC分类号： A61F2/02 , A61K31/7052 , A61K38/16 , A61K39/395 , A61K9/00 , A61P17/00 , A61P25/00 , A61P29/00 , A61P3/00 , A61P31/00 , A61P35/00 , C07H21/00 , C07K14/00 , C07K2/00 , C12N15/63
CPC分类号： C07K14/47
摘要： The present invention relates to polypeptide variants of the HMGB-1 high affinity binding domain Box-A (HMGB1 Box-A) or to a biologically active fragment of HMGB1 Box-A, which are obtained through systematic mutations of single amino acids of the wild-type HMGB1 Box-A protein and which show an increased resistance to proteases and which are therefore characterized by more favourable pharmacokinetic and pharmacodynamic profiles. Moreover, the present invention concerns the use of said polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and associated with RAGE.
摘要翻译： 本发明涉及HMGB-1高亲和力结合域Box-A（HMGB1 Box-A）或HMGB1 Box-A的生物活性片段的多肽变体，其通过野生型单个氨基酸的系统性突变获得 型HMGB1 Box-A蛋白，其表现出对蛋白酶的增加的抗性，因此其特征在于更有利的药代动力学和药效学特征。 此外，本发明涉及HMGB1 Box-A的所述多肽分子用于诊断，预防，缓解和/或治疗与细胞外HMGB1相关并与RAGE相关的病理学的用途。
-
公开(公告)号：US20110130331A1
公开(公告)日：2011-06-02
申请号：US12931218
申请日：2011-01-25
申请人： Thierry Guyon , Gilles Borrelly , Lila Drittanti , Manuel Vega
发明人： Thierry Guyon , Gilles Borrelly , Lila Drittanti , Manuel Vega
IPC分类号： A61K38/27 , C07K14/61 , A61P31/18 , A61P1/16 , A61P13/12 , A61P3/04 , A61P19/10 , A61P15/16 , A61P25/00 , A61P21/00
摘要： Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.
摘要翻译： 提供了修饰的生长激素多肽，编码修饰的生长激素多肽的核酸分子和产生修饰的生长激素多肽的方法。 还提供了使用修饰的生长激素多肽的治疗方法。
-
6.发明授权Modified growth hormones that exhibit increased protease resistance and pharmaceutical compositions thereof 有权表现出增加的蛋白酶抗性的改良生长激素及其药物组合物公开(公告)号：US08222209B2
公开(公告)日：2012-07-17
申请号：US12931218
申请日：2011-01-25
申请人： Thierry Guyon , Gilles Borrelly , Lila Drittanti , Manuel Vega
发明人： Thierry Guyon , Gilles Borrelly , Lila Drittanti , Manuel Vega
摘要： Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.
摘要翻译： 提供了修饰的生长激素多肽，编码修饰的生长激素多肽的核酸分子和产生修饰的生长激素多肽的方法。 还提供了使用修饰的生长激素多肽的治疗方法。
-
公开(公告)号：US20060247170A1
公开(公告)日：2006-11-02
申请号：US11476173
申请日：2006-06-26
申请人： Thierry Guyon , Gilles Borrelly , Lila Drittanti , Manuel Vega
发明人： Thierry Guyon , Gilles Borrelly , Lila Drittanti , Manuel Vega
摘要： Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.
摘要翻译： 提供了修饰的生长激素多肽，编码修饰的生长激素多肽的核酸分子和产生修饰的生长激素多肽的方法。 还提供了使用修饰的生长激素多肽的治疗方法。
-
8.发明授权公开(公告)号：US08383388B2
公开(公告)日：2013-02-26
申请号：US11818985
申请日：2007-06-15
申请人： Jorge Oyhenart , Xavier Gallet , Gilles Borrelly , Thierry Guyon , Manuel Vega , Lila Drittanti
发明人： Jorge Oyhenart , Xavier Gallet , Gilles Borrelly , Thierry Guyon , Manuel Vega , Lila Drittanti
CPC分类号： C12N9/644 , C12Y304/21022
摘要： Provided are modified factor IX (FIX) polypeptides and methods of generating modified FIX polypeptides. Also provided are pharmaceutical compositions, including compositions formulation for oral administration, that contain the modified FIX polypeptides, and methods of treatment using modified FIX polypeptides.
摘要翻译： 提供了修饰因子IX（FIX）多肽和产生修饰的FIX多肽的方法。 还提供了药物组合物，包括用于口服给药的组合物制剂，其含有修饰的FIX多肽，以及使用修饰的FIX多肽的治疗方法。
-
9.发明申请MODIFIED ERYTHROPOIETIN (EPO) POLYPEPTIDES THAT EXHIBIT INCREASED PROTEASE RESISTANCE AND PHARMACEUTICAL COMPOSITIONS THEREOF 审中-公开改良的抗坏血酸蛋白酶（EPO）多肽，其具有增加的抗蛋白酶和药物组合物公开(公告)号：US20120264686A9
公开(公告)日：2012-10-18
申请号：US12736959
申请日：2009-05-29
申请人： Thierry Guyon , Gilles Borrelly , Xavier Gallet , Lila Drittanti , Manuel Vega
发明人： Thierry Guyon , Gilles Borrelly , Xavier Gallet , Lila Drittanti , Manuel Vega
IPC分类号： A61K38/18 , C12N15/12 , C12N15/63 , A61P7/06 , C12N1/19 , C12N5/10 , C12N1/13 , C07K14/505 , C12N1/21
CPC分类号： C07K14/505 , A61K38/00
摘要： Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides.
摘要翻译： 提供了修饰的促红细胞生成素（EPO）多肽和其他修饰的治疗多肽。 EPO多肽和其他治疗性多肽被修饰以显示分别与未修饰的EPO多肽和其他未修饰的治疗性多肽不同的物理性质和活性。 还提供了编码这些多肽的核酸分子。 还提供了使用多肽的治疗和诊断的方法。
-
10.发明授权公开(公告)号：US08252743B2
公开(公告)日：2012-08-28
申请号：US11998387
申请日：2007-11-28
申请人： Thierry Guyon , Gilles Borrelly , Xavier Gallet , Lila Drittanti , Manuel Vega
发明人： Thierry Guyon , Gilles Borrelly , Xavier Gallet , Lila Drittanti , Manuel Vega
IPC分类号： A61K38/18 , C07K14/505
CPC分类号： C07K14/505 , A61K31/555 , A61K33/26 , A61K38/00 , A61K38/193 , A61K45/06 , Y02A50/473 , A61K2300/00
摘要： Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides.
摘要翻译： 提供了修饰的促红细胞生成素（EPO）多肽和其他修饰的治疗多肽。 EPO多肽和其他治疗性多肽被修饰以显示分别与未修饰的EPO多肽和其他未修饰的治疗性多肽不同的物理性质和活性。 还提供了编码这些多肽的核酸分子。 还提供了使用多肽的治疗和诊断的方法。
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.069 秒)
